HARBOUR BIOMED

📍 Cambridge, United States🗓 Founded 2016👥 103 employees💰 Last funded Dec 2019
Biotechnology Research🌐 harbourbiomed.com
Website LinkedIn
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com
3
Total investors
2
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
South Korea
1
United States
1
China
1
Investor activity2016–2019 · investors recorded per year
201612018120191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in HARBOUR BIOMED?
HARBOUR BIOMED has 3 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage.
When did HARBOUR BIOMED last raise funding?
The most recent investment in HARBOUR BIOMED recorded on gritt.io was in December 2019.
When was HARBOUR BIOMED founded?
HARBOUR BIOMED was founded in 2016.
What industry is HARBOUR BIOMED in?
HARBOUR BIOMED operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is HARBOUR BIOMED based?
HARBOUR BIOMED is headquartered in Cambridge, United States.